XML 32 R21.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

15.

Stock-Based Compensation

On April 30, 2015, the Company entered into a Non-qualified Stock Option Agreement with Sophie Pibouin, a director of the Company, in accordance with the 2015 Plan. The agreement granted options to purchase 2,560 shares prior to the expiration date of April 29, 2025 at an exercise price of $37.50. The options granted vested on a graded scale over a period of time through October 31, 2015.

On January 1, 2016, the Company granted employees stock options to purchase 5,000 shares at an exercise price of $45.00 per share in accordance with the 2015 Plan. The options were fully vested as of January 1, 2019. The total fair value of $196,250 for these stock options was recognized by the Company over the requisite service period.

On February 10, 2016, the Company granted employees stock options to purchase 4,200 shares at an exercise price of $48.00 per share in accordance with the 2015 Plan. The options were fully vested as of February 10, 2020. The total fair value of $174,748 for these stock options is being recognized by the Company over the requisite service period.

On December 6, 2016, the Company granted one employee stock options to purchase 2,000 shares at an exercise price of $38.00 per share in accordance with the 2015 Plan, with vesting continuing until December 2020. The total fair value of $63,937 for these stock options is being recognized by the Company over the requisite service period.

On September 25, 2017, the Company granted an employee stock options to purchase 15,000 shares at an exercise price of $15.00 per share and 10,000 shares at an exercise price of $19.00 per share, in accordance with the 2015 Plan. The options were fully vested as of September 25, 2019. The total fair value of $321,011 for these stock options was recognized by the Company over the requisite service period.

On January 30, 2019, the Company entered into a Non-qualified Stock Option Agreement with an individual consultant to the Company, in accordance with the 2015 Plan. The agreement granted options to purchase 250 shares prior to the expiration date of December 31, 2025 at an exercise price of $45.00. The options granted were 100% vested as of the grant date.

On March 11, 2019, the Company canceled previously granted stock options to employees in the following amounts: 3,000 shares at an exercise price of $45.00 per share; 3,200 shares at an exercise price of $48.00 per share; 2,000 shares at an exercise price of $38.00 per share; 15,000 shares at an exercise price of $15.00 per share; and 10,000 shares at an exercise price of $19.00 per share. On March 11, 2019, the Company replaced those canceled stock options exercisable for a total of 33,200 shares with virtually identical stock options at an exercise price of $6.50 per share in accordance with the 2015 Plan. The incremental fair value of $24,898 for these stock options is being recognized by the Company over the requisite service periods, which range by tranche from fully vested at issuance through vesting by December 2020.

On March 11, 2019, the Company granted employees stock options to purchase 10,100 shares at an exercise price of $6.50 per share in accordance with the 2015 Plan, with vesting continuing until 2023. The total fair value of $44,591 for these stock options is being recognized by the Company over the requisite service period.

On September 2, 2020, the Company granted employees stock options to purchase 99,000 shares, including 37,500 shares of performance-based options, at an exercise price of $4.00 per share in accordance with the 2015 Plan, with vesting continuing until 2024. The total fair value of $327,181 for these stock options is being recognized by the Company over the requisite service period.

The weighted average estimated values of director and employee stock option grants, as well as the weighted average assumptions that were used in calculating such values during the nine months ended September 30, 2020 and 2019, were based on estimates at the date of grant as follows:

	April 30,			January 1,			February 10,
	2015 Grant			2016 Grant			2016 Grant
Risk-free interest rate		1.43	%		1.76	%		1.15	%
Weighted average expected term		5 years			5 years			5 years
Expected volatility		143.10	%		134.18	%		132.97	%
Expected dividend yield		0.00	%		0.00	%		0.00	%

	December 6,			September 25,			January 30,
	2016 Grant			2017 Grant			2019 Grant
Risk-free interest rate		1.84	%		1.85	%		2.54	%
Weighted average expected term		5 years			5 years			5 years
Expected volatility		123.82	%		130.79	%		115.80	%
Expected dividend yield		0.00	%		0.00	%		0.00	%

	March 11,			September 2,
	2019 Grant			2020 Grant
Risk-free interest rate		2.44	%		0.26	%
Weighted average expected term		5 years			5 years
Expected volatility		116.46	%		121.33	%
Expected dividend yield		0.00	%		0.00	%

A summary of stock option activity during the nine months ended September 30, 2020 and 2019 is as follows:

					Weighted-
			Weighted-		Average
	Shares		Average		Remaining	Aggregate
	Under		Exercise		Contractual	Intrinsic
	Option		Price		Life	Value
Outstanding at January 1, 2020		46,860	$	9.02	9 years		19,200
Granted		99,000		4.00
Outstanding at September 30, 2020		145,860	$	5.61	9 years	$	19,200

Exercisable at September 30, 2020		38,785	$	9.54	8 years	$	19,200

						Weighted-
				Weighted-		Average
	Shares			Average		Remaining	Aggregate
	Under			Exercise		Contractual	Intrinsic
	Option			Price		Life	Value
Outstanding at January 1, 2019		36,760		$	25.04	8 years		79,200
Granted		43,550			6.72
Forfeited and expired		(33,450	)		43.00

Outstanding at September 30, 2019		46,860		$	9.02	9 years	$	19,200

Exercisable at September 30, 2019		34,960		$	9.87	9 years	$	19,200

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2020 was $3.30. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2019 was $4.49.

As of September 30, 2020, and December 31, 2019, there was $350,462 and $56,012, respectively, of total unrecognized compensation costs related to stock options granted under our stock option agreements. The unrecognized compensation cost is expected to be recognized over a weighted-average period of four years. The total fair value of stock options that vested during the nine months ended September 30, 2020 and 2019 was $14,963 and $105,785, respectively.